Welcome to Markets Desk, your midday read on what's moving money and markets.
The ten-year Treasury yield is pressing toward five percent, a level last seen in October of twenty twenty three, and strategists are quick to remind investors that the why matters as much as the number itself. If yields are rising because of resilient growth and strong data, that's a very different signal than yields climbing on fiscal concern or inflation expectations becoming unanchored. The distinction shapes how equities and credit respond, and right now, the market hasn't fully made up its mind on which story it's telling.
Shifting to the technology front, the AI rivalry between the United States and China is taking a sharper edge. Six Chinese AI companies were accused this week of bulk-subscribing to American AI platforms and training their own models on that output. It's an efficiency play — and a revealing one. Facing chip restrictions and limited compute, Chinese labs are closing the gap not with raw power, but with precision, and that has real implications for how Washington thinks about its export controls going forward.
And in biotech, three small-cap names — Kodiak Sciences, Capricor Therapeutics, and Invivyd — are each approaching binary catalysts before the end of twenty twenty six, with pivotal FDA decisions and trial readouts on the calendar. In this corner of the market, one data point can double a stock or cut it in half overnight, so position sizing is everything.
That's the tape. Markets Desk, signing off the floor.
